New update to Candidate List of Substances of Very High Concern (SVHCs)

New update to Candidate List of Substances of Very High Concern (SVHCs)
GarciaYbrahim

Europe 

 

New update to Candidate List of Substances of Very High Concern (SVHCs)

 

On 7th November 2024, the ECHA (European Chemicals Agency) released the new Candidate List of SVHCs with the addition of one new substance. The current list of SVHCs now contains 242 substances.

 

See below a table indicating the latest substance addition:

 

Legal obligations for companies using SVHC substances include:

  • Suppliers provide customers and consumers with enough information to allow for safe use of products that contain a substance of very high concern (SVHC) above a concentration of 0.1 % (weight by weight)

 

  • Importers and producers of these products must notify the ECHA if their article contains SVHC substances above a concentration of 0.1% weight by weight (w/w) and the substance is present in those products in quantities totalling over 1 tonne per producer or per importer per year. The notifications must be submitted within six months from the date it that the substance is included in the list.

 

  • Suppliers of substances on the Candidate List, supplied either on their own or in mixtures, must provide their customers with a safety data sheet.

 

  • Under the Waste Framework Directive (Directive 2008/98/EC on waste- WFD), any supplier of an article containing a substance of very high concern (SVHC) in a concentration above 0.1% weight by weight (w/w) on the EU market is required to submit a SCIP Notification on that article to ECHA, as of 5 January 2021. SCIP is the database holding information on Substances of Concern in articles, as such or in complex objects (products), established under the WFD. The SCIP database complements the existing notification obligations for Candidate List substances in articles subject to REACH regulation and its related communication through the supply chain, according to Articles 7 (2) and 33 respectively.

 

Please click this link to read more:https://echa.europa.eu/candidate-list-table

اترك تعليقا
All comments are moderated before being published.

اقرأ سياسة الخصوصية وشروط الخدمة.

ونحن نوصي

المنشورات ذات الصلة

  • Decoding QMSR: FDA QMSR & ISO 13485 Harmony

    فك التشفير QMSR: FDA QMSR و ISO 13485 تناغم

    ستعمل QMSR على مواءمة نظام إدارة جودة الأجهزة الطبية التابع لإدارة الغذاء والدواء مع ISO 13485: 2016. سيتم إصداره بحلول نهاية هذا العام ويصبح ساري المفعول بعد عام واحد. ومن المتوقع أن يوفر هذا التنسيق لشركات الأجهزة الطبية ما لا يقل عن 439 مليون دولار خلال العقد المقبل.
  • What Medical Importers Must Do to Stay Ahead in 2025 Regulatory Landscape

    What Medical Importers Must Do to Stay Ahead in 2025 Regulatory Landscape

    With tightening EU regulations like MDR, IVDR, RoHS, and REACH, medical importers and distributors face growing compliance and supply chain risks. This article explores key impacts, actionable steps, and how working with Medasia ensures access to certified, cost-effective, and regulation-ready medical products.

  • Latest Compliance Insights for Medical Industry CE Certification & Environmental Regulations

    Latest Compliance Insights for Medical Industry CE Certification & Environmental Regulations

    As EU MDR/IVDR and environmental rules tighten, importers face growing compliance demands. This article highlights key 2024–2025 regulatory updates, their impact on importers, and offers practical guidance for compliant sourcing and market access.

  • Home Medical Devices in China: Market Trends, Key Players & Future Outlook (2025)

    Home Medical Devices in China: Market Trends, Key Players & Future Outlook (2025)

    The demand for home medical devices in China is surging, driven by an aging population and chronic disease management needs. From blood glucose monitors to AI-driven ventilators, this $42B market is redefining global healthcare accessibility.

  • اشترك في MedInsights
  • اشترك في MedInsights
  • اشترك في MedInsights
  • اشترك في MedInsights
  • اشترك في MedInsights